Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Neurology Diagnostics Inc

Neither a doctor nor a teaching hospital

Research payments

$9,617,486

120 payments

Through program year 2025, Neurology Diagnostics Inc is reported as receiving $9,617,486 in research payments, across 120 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $496,777 12
2024 Research $1,106,183 17
2023 Research $1,996,732 39
2022 Research $2,780,346 22
2021 Research $1,924,086 20
2020 Research $632,636 6
2019 Research $680,726 4

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $8,749,879 56 payments
  2. Novartis Pharmaceuticals Corporation $460,005 10 payments
  3. AbbVie, Inc. $226,889 14 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $95,946 30 payments
  5. Amgen Inc. $40,430 1 payment
  6. ACADIA Pharmaceuticals Inc $31,317 7 payments
  7. Avanir Pharmaceuticals, Inc. $13,020 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $4,571,232 10 payments
  2. A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer's Disease (Trailblazer-Alz 2) $1,390,371 2 payments
  3. Assessment of Safety, Tolerability and Efficacy of Ly3002813 Alone and in Combination With Ly3202626 in Early Symptomatic Alzheimers Disease $1,190,678 7 payments
  4. Donanemab Follow-On Study: Safety, Tolerability, and Efficacy in Symptomatic Alzheimer's Disease With Validation of Remote Neuropsychological Assessments $396,191 7 payments
  5. A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed By Extended Treatment With Open-Label Remibrutinib $391,810 5 payments
  6. Assessment of Safety, Tolerability, and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer's Disease $266,853 6 payments
  7. Assessment of Safety Tolerability and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer's Disease $218,176 2 payments
  8. A Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Finding Study Evaluating Ly3848575 in Chronic Neuropathic Pain Associated With Distal Sensory Polyneuropathy $204,291 2 payments
  9. Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease $156,473 2 payments
  10. A Donanemab (Ly3002813) Prevention Study in Participants With Alzheimer's Disease (Trailblazer-Alz 3) $146,880 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record